Curis is announcing that it has achieved the previously stated goal of dosing the ﬁrst ﬁve patients in the TakeAim CLL study and reafﬁrmed its expectation to report initial CLL data in 5-10 patients in December 2026.

emavusertib (CA-4948) - Curis

Jul 30, 2026